Multiple regression analysis of pharmaeogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers

被引:41
作者
Honda, M
Ogura, Y
Toyoda, W
Taguchi, M
Nozawa, T
Inoue, H
Hashimoto, Y
机构
[1] Toyama Univ, Grad Sch Pharmaceut Sci, Toyama 9300194, Japan
[2] Toyama Univ, Fac Med, Dept Internal Med 2, Toyama 9300194, Japan
关键词
carvedilol; CYP2D6*10; pharmacokinetics; Bayesian analysis;
D O I
10.1248/bpb.29.772
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to evaluate the pharmacogenetic variability in the disposition of carvedilol in the Japanese population. Five or 10 mg of carvedilol was orally administered to 54 healthy Japanese subjects (22-44 years old), and blood samples were taken at 2 and 6 h after dosing. We determined the polymorphic alleles of CYP2D6, CYP2C9, CYP209, CYP3A5, UGT2B7, and MDR1 in each subject. The whole blood concentration of R- and S-carvedilol was measured by an HPLC method. The pharmacokinetic parameters in individual subjects were estimated by the Bayesian method using the nonlinear mixed effects model (NONMEM) program. We then examined the effect of the genetic polymorphisms on the variability in the pharmacokinetics of carvedilol using a multiple regression analysis. The oral clearance (CLIF) and also apparent volume of distribution (VIF) of both enantiomers were significantly lower in the subjects with the CYP2D6*10 allele than those with the CYP2D6*1/*1, *1/*2, or *2/*2 genotype, confirming our previous finding that the bioavailability (F) and systemic clearance (CL) of R- and S-carvedilol in the liver is significantly altered in Japanese with the CYP2D6*10 allele. On the other hand, CYP2C9*3, CYP2C19*2, CYP2C19*3, CYP3A5*3, UGT2B7*2, and MDR1 C3435T did not significantly affect the pharmacokinetics of carvedilol in Japanese subjects.
引用
收藏
页码:772 / 778
页数:7
相关论文
共 34 条
  • [1] BEAL SL, 1992, NONMEM USERS GUIDES
  • [2] Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes:: Specificity and influence of the UGT2B7*2 polymorphism
    Court, MH
    Krishnaswamy, S
    Hao, Q
    Duan, SX
    Patten, CJ
    Von Moltke, LL
    Greenblatt, DJ
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (09) : 1125 - 1133
  • [3] EGGERTSEN R, 1987, J CARDIOVASC PHA S11, V10, P97
  • [4] ASSAY AND DISPOSITION OF CARVEDILOL ENANTIOMERS IN HUMANS AND MONKEYS - EVIDENCE OF STEREOSELECTIVE PRESYSTEMIC METABOLISM
    FUJIMAKI, M
    MURAKOSHI, Y
    HAKUSUI, H
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1990, 79 (07) : 568 - 572
  • [5] CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects
    Giessmann, T
    Modess, C
    Hecker, U
    Zschiesche, M
    Dazert, P
    Kunert-Keil, C
    Warzok, R
    Engel, G
    Weitschies, W
    Cascorbi, I
    Kroemer, HK
    Siegmund, W
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (03) : 213 - 222
  • [6] C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation
    Goto, M
    Masuda, S
    Saito, H
    Uemoto, S
    Kiuchi, T
    Tanaka, K
    Inui, K
    [J]. PHARMACOGENETICS, 2002, 12 (06): : 451 - 457
  • [7] Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
    Hesselink, DA
    van Schaik, RHN
    van der Heiden, IP
    van der Werf, M
    Gregoor, PJHS
    Lindemans, J
    Weimar, W
    van Gelder, T
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (03) : 245 - 254
  • [8] Functional polymorphisms of the human multidrug-resistance gene:: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
    Hoffmeyer, S
    Burk, O
    von Richter, O
    Arnold, HP
    Brockmöller, J
    Johne, A
    Cascorbi, I
    Gerloff, T
    Roots, I
    Eichelbaum, M
    Brinkmann, U
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) : 3473 - 3478
  • [9] Effect of CYP2D6*10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers
    Honda, M
    Nozawa, T
    Igarashi, N
    Inoue, H
    Arakawa, R
    Ogura, Y
    Okabe, H
    Taguchi, M
    Hashimoto, Y
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2005, 28 (08) : 1476 - 1479
  • [10] Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes
    Huang, JD
    Chuang, SK
    Cheng, CL
    Lai, ML
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (04) : 402 - 407